Poly(ADP-ribose) polymerase inhibitors: New pharmacological functions and potential clinical implications

Current Pharmaceutical Design

Volumn 13, Issue 9, 2007, Pages 933-962

  Alarcon de la Lastra C ^a   Villegas, I ^a   Sanchez Fidalgo S ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Cancer; Diabetes; Iinflammation; PARP

Indexed keywords

3 AMINOBENZAMIDE; 8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; AG 14361; BENZAMIDE DERIVATIVE; BENZIMIDAZOLE; CAMPTOTHECIN; CEP 6800; DNA TOPOISOMERASE INHIBITOR; GPI 15427; GPI 16539; GPI 6150; INO 1001; IRINOTECAN; METHYLTRANSFERASE INHIBITOR; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 10; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 4; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 5A; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 5B; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 7; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TEMOZOLOMIDE; TOPOTECAN; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLERGY; ALZHEIMER DISEASE; ASTHMA; ASTROCYTOMA; BONE MARROW SUPPRESSION; BRAIN TUMOR; CELL DEATH; CLINICAL TRIAL; COLITIS; CYTOTOXICITY; DEGENERATIVE DISEASE; DIABETES MELLITUS; DNA DAMAGE; DNA REPAIR; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG DOSE REGIMEN; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG WITHDRAWAL; ENDOTHELIUM LESION; ENTERITIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; GENOMICS; GLIOMA; HEART INFARCTION; HUMAN; INFECTION CONTROL; INFLAMMATORY DISEASE; IONIZING RADIATION; LONGEVITY; MELANOMA; MULTIPLE ORGAN FAILURE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS; SHOCK; STROKE; UPREGULATION; VIRUS INFECTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; ENZYME INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; POLY(ADP-RIBOSE) POLYMERASES; PROTECTIVE AGENTS; PROTEIN SUBUNITS;

EID: 34247324385     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780414241     Document Type: Review

References (385)

1. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADP-ribosyl) ation reactions in the regulation of nuclear functions. Biochem J 1999; 342: 249-68.
2. Amé JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004; 26: 1-12.
3. Nguewa PA, Fuertes MA, Valladares B, Alonso C, Perez JM. Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications. Prog Biophys Mol Biol 2005; 88: 143-72.
4. +. FEBS J 2005; 272: 4576-89.
5. Brown JA, Marala RB. Development of a high-throughput screening-amenable assay for human poly(ADP-ribose) polymerase inhibitors. J Pharmacol Toxicol Methods 2002; 47:137-41.
6. Ogata N, Ueda K, Hayaishi O. ADP-ribosylation of histone H2B. Identification of glutamic acid residue 2 as the modification site. J Biol Chem 1980; 255: 7610-15.
7. Diefenbach J, Burkle A. Introduction to poly(ADP-ribose) metabolism. Cell Mol Life Sci 2005; 62: 721-30.
8. Adamietz P, Rudolph A. ADP-ribosylation of nuclear proteins in vivo. Identification of histone H2B as a major acceptor for mono-and poly(ADP-ribose) in dimethyl sulfate-treated hepatoma AH 7974 cells. J Biol Chem 1984; 259: 6841-46.
9. Mendoza-Alvarez H, Alvarez-Gonzales R. Regulation of p53 sequence-specific DNA-binding by covalent poly(ADP-ribosyl)ation. J Biol Chem 2001; 276: 36425-30.
10. Kameoka M, Ota K, Tetsuka T, Tanaka Y, Itaya A, Okamoto T, et al. Evidence for regulation of NF-kappaB by poly(ADP-ribose) polymerase. Biochem J 2000; 346 3: 641-9.
11. Simbulan CM, Suzuki M, Izuta S, Sakurai T, Savoysky E, Kojima K, et al. Poly(ADP-ribose) polymerase stimulates DNA polymerase alpha by physical association. J Biol Chem 1993; 268: 93-9.
12. Oei SL, Griesenbeck J, Schweiger M, Ziegler M. Regulation of RNA polymerase II-dependent transcription by poly(ADP-ribosyl) ation of transcription factors. J Biol Chem 1998; 273: 31644-7.
13. Oei SL, Ziegler M. ATP for the DNA ligation step in base excision repair is generated from poly(ADP-ribose). J Biol Chem 2000; 275: 23234-9.
14. Cervantes-Laurean D, Jacobson EL, Jacobson MK Glycation and glycoxidation of histones by ADP-ribose J Biol Chem 1996; 27: 10461-9.
15. Meyer-Ficca ML, Meyer RG, Coyle DL, Jacobson EL, Jacobson MK. Human poly(ADP-ribose) glycohydrolase is expressed in alternative splice variants yielding isoforms that localize to different cell compartments. Exp Cell Res 2004; 297: 521-32.
16. Chambon P, Weill JD, Mandel P. Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun 1963; 11: 39-43.
17. Ikejima M, Noguchi S, Yamashita R, Ogura T, Sugimura T, Gill DM, et al. The zinc fingers of human poly(ADP-ribose) polymerase are differentially required for the recognition of DNA breaks and nicks and the consequent enzyme activation. Other structures recognize intact DNA. J Biol Chem 1990; 265: 21907-13.
18. Huyton T, Bates PA, Zhang X, Sternberg MJ, Freemont PS. The BRCA1 C-terminal domain: structure and function. Mutat Res 2000; 460: 319-32.
19. Virág L, Szabó C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002; 54, 375-429.
20. Simonin F, Poch O, Delarue M, de Murcia G. Identification of potential active-site residues in the human poly(ADP-ribose) polymerase. J Biol Chem 1993; 268: 8529-35.
21. Smith S. The world according to PARP. Trends Biochem Sci 2001; 26: 174-9.
22. + depletion and cell death induced by oxidative stress. J Biol Chem 2003; 278: 18426-33.
23. Bouchard VJ, Rouleau M, Poirier GG. PARP-1, a determinant of cell survival in response to DNA damage. Exp Hematol 2003; 31: 446-54.
24. Bürkle A. Physiology and pathophysiology of poly(ADP-ribosyl)ation. BioEssays 2001; 23: 795-806.
25. Hsiao SJ, Poitras MF, Cook BD, Liu Y, Smith S. Tankyrase 2 poly(ADP-ribose) polymerase domain-deleted mice exhibit growth defects but have normal telomere length and capping. Mol Cell Biol 2006; 26: 2044-54.
26. Arnold J, Grune T. PARP-mediated proteasome activation: a coordination of DNA repair and protein degradation? Bioessays 2002; 24: 1060-5.
27. Tramontano F, Di Meglio S, Quesada P. Co-localization of poly(ADPR)polymerase 1 (PARP-1) poly(ADPR)polymerase 2 (PARP-2) and related proteins in rat testis nuclear matrix defined by chemical cross-linking. J Cell Biochem 2005; 94: 58-66.
28. Meder VS, Boeglin M, de Murcia G, Schreiber V. PARP-1 and PARP-2 interact with nucleophosmin/B23 and accumulate in transcriptionally active nucleoli. J Cell Sci 2005; 118: 211-22.
29. Saxena A, Saffery R, Wong LH, Kalitsis P, Choo KH. Centromere proteins Cenpa, Cenpb, and Bub3 interact with poly(ADP-ribose) polymerase-1 protein and are poly(ADP-ribosyl)ated. J Biol Chem 2002; 277: 26921-6.
30. Saxena A, Wong LH, Kalitsis P, Earle E, Shaffer LG, Choo KH. Poly(ADP-ribose) polymerase 2 localizes to mammalian active centromeres and interacts with PARP-1, Cenpa, Cenpb and Bub3, but not Cenpc. Hum Mol Genet 2002; 11: 2319-29.
31. Dantzer F, Giraud-Panis MJ, Jaco I, Ame JC, Schultz I, Blasco M, et al. Functional interaction between poly(ADP-Ribose) polymerase 2 (PARP-2) and TRF2: PARP activity negatively regulates TRF2. Mol Cell Biol 2004; 24: 1595-607.
32. Maeda Y, Hunter TC, Loudy DE, Dave V, Schreiber V, Whitsett JA. PARP-2 interacts with TTF-1 and regulates expression of surfactant protein-B. J Biol Chem 2006; 7: 9600-6.
33. Benchoua A, Couriaud C, Guegan C, Tartier L, Couvert P, Friocourt G, et al. Active caspase-8 translocates into the nucleus of apoptotic cells to inactivate poly(ADP-ribose) polymerase-2. J Biol Chem 2002; 277: 34217-22.
34. Kanai M, Uchida M, Hanai S, Uematsu N, Uchida K, Miwa M. Poly(ADP-ribose) polymerase localizes to the centrosomes and chromosomes. Biochem Biophys Res Commun 2000; 278: 385-9.
35. Augustin A, Spenlehauer C, Dumond H, Menissier-De Murcia J, Piel M, Schmit AC, et al. PARP-3 localizes preferentially to the daughter centriole and interferes with the G1/S cell cycle progression. J Cell Sci 2003; 116: 1551-62.
36. Tarapore P, Tokuyama Y, Horn HF, Fukasawa K. Difference in the centrosome duplication regulatory activity among p53 'hot spot' mutants: potential role of Ser 315 phosphorylation-dependent centrosome binding of p53. Oncogene 2001; 20: 6851-63.
37. Kanai M, Tong WM, Sugihara E, Wang ZQ, Fukasawa K, Miwa M. Involvement of poly(ADP-Ribose) polymerase 1 and poly(ADP-Ribosyl)ation in regulation of centrosome function. Mol Cell Biol 2003; 23: 2451-62.
38. Kickhoefer VA, Siva AC, Kedersha NL, Inman EM, Ruland C, Streuli M, Rome LHThe 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase. J Cell Biol 1999; 146: 917-28.
39. van Zon A, Mossink MH, Scheper RJ, Sonneveld P, Wiemer EA. The vault complex. Cell Mol Life Sci 2003; 60: 1828-37.
40. Raval-Fernandes S, Kickhoefer VA, Kitchen C, Rome LH. Increased susceptibility of vault poly(ADP-ribose) polymerase-deficient mice to carcinogen-induced tumorigenesis. Cancer Res 2005; 65: 8846-52.
41. Smith S, Giriat I, Schmitt A, de Lange T. Tayrase, a poly(ADP-ribose) polymerase at human telomeres. Science (Washington, DC) 1998; 282: 1484-7.
42. Kim CA, Bowie JU. SAM domains: uniform structure, diversity of function. Trends Biochem Sci 2003; 28: 625-8.
43. Chi NW, Lodish H. Tankyrase is a golgi-associated mitogen-activated protein kinase substrate that interacts with IRAP in GLUT4 vesicles. J Biol Chem 2000; 275: 38437-44.
44. Seimiya H. The telomeric PARP, tankyrases, as targets for cancer therapy. Br J Cancer 2006; 94: 341-5.
45. Wittmann T, Hyman A, Desai A. The spindle: a dynamic assembly of microtubules and motors. Nat Cell Biol 2001; 3: E28-34.
46. Chang P, Coughlin M, Mitchison TJ. Tankyrase-1 polymerization of poly(ADP-ribose) is required for spindle structure and function. Nat Cell Biol 2005; 7: 1133-9.
47. Seimiya H, Smith S.The telomeric poly(ADP-ribose) polymerase, tankyrase 1, contains multiple binding sites for telomeric repeat binding factor 1 (TRF1) and a novel acceptor, 182-kDa tankyrase-binding protein (TAB182). J Biol 2002; 277: 14116-26.
48. Kaminker PG, Kim SH, Taylor RD, Zebarjadian Y, Funk WD, Morin GB, et al. TANK2, a new TRF1-associated poly(ADP-ribose) polymerase, causes rapid induction of cell death upon overexpression. J Biol Chem 2001; 276: 35891-9.
49. Cook BD, Dynek JN, Chang W, Shostak G, Smith S. Role for the related poly(ADP-Ribose) polymerases tankyrase 1 and 2 at human telomeres. Mol Cell Biol 2002; 22: 332-42.
50. Sidorova N, Zavalishina L, Kurchashova S, Korsakova N, Nazhimov V, Frank G, et al. Immunohistochemical detection of tankyrase 2 in human breast tumors and normal renal tissue. Cell Tissue Res 2006; 323:137-45.
51. De Rycker M, Venkatesan RN, Wei C, Price CM. Vertebrate tankyrase domain structure and sterile alpha motif (SAM)-mediated multimerization. Biochem J 2003; 372: 87-96.
52. Ma Q, Baldwin KT, Renzelli AJ, McDaniel A, Dong L.TCDD-inducible poly(ADP-ribose) polymerase: a novel response to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Biochem Biophys Res Commun 2001; 289: 499-506.
53. Ma Q. Induction and superinduction of 2,3,7,8-tetrachlorodibenzorho-dioxin-inducible poly(ADP-ribose) polymerase: role of the aryl hydrocarbon receptor/aryl hydrocarbon receptor nuclear translocator transcription activation domains and a labile transcription repressor. Arch Biochem Biophys 2002; 404: 309-16.
54. Yu M, Schreek S, Cerni C, Schamberger C, Lesniewicz K, Poreba E, et al. PARP-10, a novel Myc-interacting protein with poly(ADP-ribose) polymerase activity, inhibits transformation. Oncogene 2005; 24: 1982-93.
55. Durkacz BW, Omidiji O, Gray DA, Shall S. (ADP-ribose)n participates in DNA excision repair. Nature 1980; 283: 593-6.
56. Prasad SC, Thraves PJ, Bhatia KG, Smulson ME, Dritschilo A. Enhanced poly(adenosine diphosphate ribose) polymerase activity and gene expression in Ewing's sarcoma cells. Cancer Res 1990; 50: 38-43.
57. Tomoda T, Kurashige T, Moriki T, Yamamoto H, Fujimoto S, Taniguchi T. Enhanced expression of poly(ADP-ribose) synthetase gene in malignant lymphoma. Am J Hematol 1991; 37: 223-7.
58. Shiobara M, Miyazaki M, Ito H, Togawa A, Nakajima N, Nomura F, et al. Enhanced polyadenosine diphosphate-ribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2001; 16: 338-44.
59. Tentori L, Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 2005; 52: 25-33.
60. Griffin RJ, Curtin NJ, Newell DR, Golding BT, Durkacz BW, Calvert AH. The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy. Biochimie 1995; 77: 408-22.
61. Horsman MR. Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. A review. Acta Oncol 1995; 34: 571-87.
62. Bower M, Newlands ES, Bleehen NM, Brada M, Begent RJ, Calvert H, et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive highgrade glioma. Cancer Chemother Pharmacol 1997; 40: 484-8.
63. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, et al. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001; 12: 259-66.
64. Stupp R, van den Bent MJ, Hegi ME. Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep 2005; 5: 198-206.
65. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, preclinical development and clinical trials. Cancer Treat Rev 1997; 23: 35-61.
66. Gerson SL. MGMT: its role in cancer aetiology and cancer theapeutics. Nat Rev Cancer 2004; 4: 296-307.
67. D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, et al. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol 1998; 54: 334-41.
68. Tentori L, Graziani G. Pharmacological strategies to increase the antitumor activity of methylating agents. Curr Med Chem 2002; 9: 1285-301.
69. Curtin NJ, Wang LZ, Yiakouvaki A, Kyle S, Arris CA, Canan-Koch S, et al. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin Cancer Res 2004; 10: 881-9.
70. Cheng CL, Johnson SP, Keir ST, Quinn JA, Ali-Osman F, Szabó C, et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther 2005; 4: 1364-8.
71. Han HJ, Yanagisawa A, Kato Y, Park JG, Nakamura Y. Genetic instability in pancreatic cancer and poorly differentiated type of gastric cancer. Cancer Res 1993; 53: 5087-9.
72. Shridhar V, Siegfried J, Hunt J, del Mar Alonso M, Smith DI. Genetic instability of microsatellite sequences in many nonsmall cell lung carcinomas. Cancer Res 1994; 54: 2084-7.
73. Wooster R, Cleton-Jansen AM, Collins N, Mangion J, Cornelis RS, Cooper CS, et al. Instability of short tandem repeats (microsatellites) in human cancers. Nat Genet 1994; 6: 152-6.
74. Ben-Yehuda D, Krichevsky S, Caspi O, Rund D, Polliack A, Abeliovich D, et al. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 1996; 88: 4296-303.
75. Indraccolo S, Minuzzo S, Nicoletti L, Cretella E, Simon M, Papakonstantinou G, et al. Mutator phenotype in human hematopoietic neoplasms and its association with deletions disabling DNA repair genes and bcl-2 rearrangements. Blood 1999; 94: 2424-32.
76. Tentori L, Portarena I, Barbarino M, Balduzzi A, Levati L, Vergati M, et al. Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (ADP-ribose) polymerase inhibitor. Mol Pharmacol 2003; 63: 192-202.
77. Tentori L, Lacal PM, Benincasa E, Franco D, Faraoni I, Bonmassar E, et al. Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with inhibitors of poly(ADP-ribose) polymerase. J Pharmacol Exp Ther 1998; 285: 884-93.
78. Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin NJ, et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 2000; 6: 2860-7.
79. Tentori L, Portarena I, Graziani G. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol Res 2002; 45: 73-85.
80. Graziani G, Szabó C. Clinical perspectives of PARP inhibitors. Pharmacol Res 2005; 52: 109-18.
81. Curtin NJ. PARP inhibitors for cancer therapy. Expert Rev Mol Med 2005; 7: 1-20.
82. Miknyoczki SJ, Jones-Bolin S, Pritchard S, Hunter K, Zhao H, Wan W, et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003; 2: 371-82.
83. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004; 96: 56-67.
84. Calabrese CR, Batey MA, Thomas HD, Durkacz BW, Wang LZ, Kyle S, et al. Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res 2003; 9: 2711-8.
85. White AW, Curtin NJ, Eastman BW, Golding BT, Hostomsky Z, Kyle S, et al. Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors. Bioorg Med Chem Lett 2004; 14: 2433-7.
86. Tentori L, Leonetti C, Scarsella M, d'Amati G, Portarena I, Zupi G, et al. Combined treatment with temozolomide and poly(ADPribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood 2002; 99: 2241-4.
87. Tentori L, Leonetti C, Scarsella M, D'Amati G, Vergati M, Portarena I, et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 2003; 9: 5370-9.
88. Tentori L, Leonetti C, Scarsella M, Vergati M, Xu W, Calvin D, et al. Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. Int J Oncol 2005; 26: 415-22.
89. Plummer ER, Middleton MR, Jones C, Olsen A, Hickson I, McHugh P, et al. Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin Cancer Res 2005; 11: 3402-9.
90. Tentori L, Vernole P, Lacal PM, Madaio R, Portarena I, Levati L, et al. Cytotoxic and clastogenic effects of a DNA minor groove binding methyl sulfonate ester in mismatch repair deficient leukemic cells. Leukemia 2000; 14: 1451-9.
91. Tentori L, Balduzzi A, Portarena I, Levati L, Vernole P, Gold B, et al. Poly (ADP-ribose) polymerase inhibitor increases apoptosis and reduces necrosis induced by a DNA minor groove binding methyl sulfonate ester. Cell Death Differ 2001; 8: 817-28.
92. Dantzer F, Schreiber V, Niedergang C, Trucco C, Flatter E, De La Rubia G, et al. Involvement of poly(ADP-ribose) polymerase in base excision repair. Bochimie 1999; 81: 69-75.
93. Tentori L, Portarena I, Vernole P, Gold B, Graziani G. Apoptotic and genotoxic effects of a methyl sulfonate ester that selectively generates N3-methyladenine and poly(ADP-ribose) polymerase inhibitors in normal peripheral blood lymphocytes. Cancer Chemother Pharmacol 2002; 49: 217-24.
94. Tentori L, Forini O, Fossile E, Muzi A, Vergati M, Portarena I, et al. N3-methyladenine induces early poly(ADP-ribosylation), reduction of nuclear factor-kappa B DNA binding ability, and nuclear up-regulation of telomerase activity. Mol Pharmacol 2005; 67: 572-81.
95. Fronza G, Gold B. The biological effects of N3-methyladenine. J Cell Biochem 2004; 91: 250-7.
96. Kaufmann SH, Charron M, Burke PJ, Karp JE. Changes in topoisomerase I levels and localization during myeloid maturation in vitro and in vivo. Cancer Res 1995; 55: 1255-60.
97. Park SY, Cheng YC. Poly(ADP-ribose) polymerase-1 could facilitate the religation of topoisomerase I-linked DNA inhibited by camptothecin. Cancer Res 2005; 65: 3894-902.
98. Malanga M, Althaus FR. Poly (ADP-ribose) reactivates stalled DNA topoisomerase I and induces DNA strand breaks resealing. J Biol Chem 2004; 279: 5244-8.
99. Malanga M, Althaus FR. The role of poly(ADP-ribose) in the DNA damage signalling network. Biochem Cell Biol 2005; 83: 354-64.
100. Martin MJ. Current stage-specific chemotherapeutic options in colon cancer. Expert Rev Anticancer Ther 2005; 5: 695-704.
101. Mattern MR, Mong SM, Bartus HF, Mirabelli CK, Crooke ST, Johnson RK. Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. Cancer Res 1987; 47: 1793-8.
102. Boulton S, Kyle S, Durkacz BW. Interactive effects of inhibitors of poly(ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. Carcinogenesis 1999; 20: 199-203.
103. Daido S, Yamamoto A, Fujiwara K, Sawaya R, Kondo S, Kondo Y. Inhibition of the DNA-dependent protein kinase catalytic subunit radiosensitizes malignant glioma cells by inducing autophagy. Cancer Res 2005; 65: 4368-75.
104. Fernet M, Ponette V, Deniaud-Alexandre E, Menissier-De Murcia J, De Murcia G, Giocanti N, et al. Poly(ADP-ribose) polymerase, a major determinant of early cell response to ionizing radiation. Int J Radiat Biol 2000; 76: 1621-9.
105. Weinfeld M, Chaudhry MA, D'Amours D, Pelletier JD, Poirier GG, Povirk LF, et al. Interaction of DNA-dependent protein kinase and poly(ADP-ribose) polymerase with radiation-induced DNA strand breaks. Radiat Res 1997; 148: 22-8.
106. Ruscetti T, Lehnert BE, Halbrook J, Le Trong H, Hoekstra MF, Chen DJ, et al. Stimulation of the DNA-dependent protein kinase by poly(ADP-ribose) polymerase. J Biol Chem 1998; 273: 14461-7.
107. Veuger SJ, Curtin NJ, Smith GC, Durkacz BW. Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair. Oncogene 2004; 23: 7322-9.
108. Brock WA, Milas L, Bergh S, Lo R, Szabó C, Mason KA. Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett 2004; 205: 155-60.
109. Wang ZQ, Auer B, Stingl L, Berghammer H, Haidacher D, Schweiger M, et al. Mice lacking ADPRT and poly(ADPribosyl) ation develop normally but are susceptible to skin disease. Genes Dev 1995; 9: 509-20.
110. de Murcia JM, Niedergang C, Trucco C, Ricoul M, Dutrillaux B, Mark M, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci USA 1997; 94: 7303-7.
111. Simbulan-Rosenthal CM, Haddad BR, Rosenthal DS, Weaver Z, Coleman A, Luo R, et al. Chromosomal aberrations in PARP(-/-) mice: genome stabilization in immortalized cells by reintroduction of poly(ADP-ribose) polymerase cDNA. Proc Natl Acad Sci USA 1999; 96: 13191-6.
112. Shall S, de Murcia G. Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat Res 2000; 460: 1-15.
113. Masutani M, Nozaki T, Nishiyama E, Shimokawa T, Tachi Y, Suzuki H, et al. Function of poly(ADP-ribose) polymerase in response to DNA damage: gene-disruption study in mice. Mol Cell Biochem 1999; 193: 149-52.
114. Nozaki T, Fujihara H, Watanabe M, Tsutsumi M, Nakamoto K, Kusuoka O, et al. Parp-1 deficiency implicated in colon and liver tumorigenesis induced by azoxymethane. Cancer Sci 2003; 94: 497-500.
115. Tsutsumi M, Masutani M, Nozaki T, Kusuoka O, Tsujiuchi T, Nakagama H, et al. Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout mice to nitrosamine carcinogenicity. Carcinogenesis 2001; 22: 1-3.
116. Conde C, Mark M, Oliver FJ, Huber A, de Murcia G, Menissier-de Murcia J. Loss of poly(ADP-ribose) polymerase-1 causes increased tumour latency in p53-deficient mice. EMBO J 2001; 20: 3535-43.
117. Shibata A, Kamada N, Masumura K, Nohmi T, Kobayashi S, Teraoka H, et al. Parp-1 deficiency causes an increase of deletion mutations and insertions/rearrangements in vivo after treatment with an alkylating agent. Oncogene 2005; 24: 1328-37.
118. Simbulan-Rosenthal CM, Rosenthal DS, Luo R, Li JH, Zhang J, Smulson ME. Inhibition of poly(ADP-ribose) polymerase activity is insufficient to induce tetraploidy. Nucleic Acids Res 2001; 29: 841-9.
119. Virág L. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies. Curr Vasc Pharmacol 2005; 3: 209-14.
120. Love S, Barber R, Wilcock GK. Increased poly(ADPribosyl) ation of nuclear proteins in Alzheimer's disease. Brain 1999; 122: 247-53.
121. Virág L. Poly(ADP-ribosyl)ation in asthma and other lung diseases. Pharmacol Res 2005; 52: 83-92.
122. Cuzzocrea S, Mazzon E, Di Paola R, Genovese T, Patel NS, Muia C, et al. 5-Aminoisoquinolinone reduces colon injury by experimental colitis. Naunyn Schmiedebergs Arch Pharmacol 2004; 370: 464-73.
123. Kitamura T, Sekimata M, Kikuchi S, Homma Y. Involvement of poly(ADP-ribose) polymerase 1 in ERBB2 expression in rheumatoid synovial cells. Am J Physiol Cell Physiol 2005; 289: C82-8.
124. Szabó G, Liaudet L, Hagl S, Szabó C. Poly(ADP-ribose)polymerase activation in the reperfused myocardium. Cardiovascular Res 2004; 61: 471-80.
125. Chiarugi A. Poly(ADP-ribosyl)ation and stroke. Pharmacol Res 2005; 52: 15-24.
126. Mabley JG, Jagtap P, Perretti M, Getting SJ, Salzman AL, Virág L, et al. Antiinflammatory effects of a novel, potent inhibitor of poly (ADP-ribose) polymerase. Inflamm Res 2001; 50: 561-9.
127. Lohinai Z, Mabley JG, Feher E, Marton A, Komjati K, Szabó C. Role of the activation of the nuclear enzyme poly(ADPribose) polymerase in the pathogenesis of periodontitis. J Dent Res 2003; 82: 987-92.
128. Di Paola R, Mazzon E, Zito D, Maiere D, Britti D, Genovese T, et al. Effects of Tempol, a membrane-permeable radical scavenger, in a rodent model periodontitis. J Clin Periodontol 2005; 32: 1062-8.
129. Balachandra S, Genovese T, Mazzon E, Di Paola R, Thiemerman C, Siriwardena AK, et al. Inhibition of tyrosine-kinase-mediated cellular signaling by tyrphostins AG 126 and AG556 modulates murine experimental acute pancreatitis. Surgery 2005; 138: 913-23.
130. Mota RA, Sanchez-Bueno F, Saenz L, Hernandez-Espinosa D, Jimeno J, Tornel PL, et al. Inhibition of poly(ADP-ribose) polymerase attenuates the severity of acute pancreatitis and associated lung injury. Lab Invest 2005; 85: 1250-62.
131. Rueda B, Koeleman BP, Lopez-Nevot MA, Ortega E, Maldonado J, Lopez M, et al. Poly (ADP-ribose) polymerase-1 haplotypes are associated with coeliac disease. Int J Immunogenet 2005; 32: 245-8.
132. Devalaraja-Narashimha K, Singaravelu K, Padanilam BJ. Poly(ADP-ribose) polymerase-mediated cell injury in acute renal failure. Pharmacol Res 2005; 52: 44-59.
133. Zheng J, Devalaraja-Narashimha K, Singaravelu K, Padanilam BJ. Poly(ADP-ribose) polymerase-1 gene ablation protects mice from ischemic renal injury. Am J Physiol Renal Physiol 2005; 288: F387-98.
134. Koedel U, Winkler F, Angele B, Fontana A, Pfister HW. Meningitis-associated central nervous system complications are mediated by the activation of poly(ADP-ribose) polymerase. J Cereb Blood Flow Metab 2002; 22: 39-49.
135. Virág L, Szabó E, Bakondi E, Bai P, Gergely P, Hunyadi J, et al. Nitric oxide-peroxynitrite-poly(ADP-ribose) polymerase pathway in the skin. Exp Dermatol 2002; 11: 189-202.
136. Oliver FJ, Menissier-de Murcia J, Nacci C, Decker P, Andriantsitohaina R, Muller S, et al. Resistance to endotoxic shock as a consequence of defective NF-kB activation in poly(ADP-ribose) polymerase-1 deficient mice. EMBO J 1999; 18: 4446-54.
137. Veres B, Gallyas F Jr, Varbiro G, Berente Z, Osz E, Szekeres G, et al. Decrease of the inflammatory response and induction of the Akt/ protein kinase B pathway by poly-(ADP-ribose) polymerase 1 inhibitor in endotoxin-induced septic shock. Biochem Pharmacol 2003; 65: 1373-82.
138. Evgenov OV, Liaudet L. Role of nitrosative stress and activation of poly(ADP-ribose) polymerase-1 in cardiovascular failure associated with septic and hemorrhagic shock. Curr Vasc Pharmacol 2005; 3: 293-9.
139. Mabley JG, Horvath EM, Murthy KG, Zsengeller Z, Vaslin A, Benko R, et al. Gender differences in the endotoxin-induced inflammatory and vascular responses: potential role of poly(ADP-ribose) polymerase activation. J Pharmacol Exp Ther 2005; 315: 812-20.
140. Hassa PO, Hottiger MO. The functional role of poly(ADP-ribose) polymerase 1 as novel coactivator of NF-kappaB in inflammatory disorders. Cell Mol Life Sci 2002; 59: 1534-53.
141. Jagtap P, Szabó C. Poly (ADP-ribose)polymerase inhibitors. Nat Rev Drug Discov 2005; 4: 421-40.
142. Geboes K. From inflammation to lesion. Acta Gastroenterol Belg 1994; 57: 273-84.
143. Rodríguez F J. Fisiopatología de la inflamaciín. In: Consejo General de Colegios Oficiales de Farmacéuticos Ed, Avances en Farmacología y Farmacoterapia. Módulo III: Avances en Inmunología, Inflamación y Dolor. Madrid, Acción Médica S A 2003; 49-74.
144. Wang SC, Rossignol DP, Christ WJ, Geller DA, Freeswick PD, Thai NL, et al. Suppression of lipopolysaccharide-induced macrophage nitric oxide and cytokine production in vitro by a novel lipopolysaccharide antagonist. Surgery 1994; 116: 339-46.
145. Rainger GE, Rowley AF, Nash GB. Adhesiondependent release of elastase from human neutrophils in a novel, flow-based model: specificity of different chemotactic agents. Blood 1998; 92: 4819-27.
146. Nathan C. Points of control in inflammation. Nature 2002; 420: 846-52.
147. Nose K. Role of reactive oxygen species in the regulation of physiological functions. Biol Pharm Bull 2000; 23: 897-903.
148. Inoue M, Sato EF, Nishikawa M, Park AM, Kira Y, Imada I, et al. Mitochondrial generation of reactive oxygen species and its role in aerobic life. Curr Med Chem 2003; 10: 2495-2505.
149. Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J 1996; 313: 17-29.
150. Marnett LJ. Oxyradicals and DNA damage. Carcinogenesis 2000; 21: 361-70.
151. Halliwell B, Aruoma OI. DNA damage by oxygen-derived species. Its mechanism and measurement in mammalian systems. FEBS Lett 1991; 281: 9-19.
152. Szabó C. Poly(ADP-ribose)polymerase activation by reactive nitrogen species-Relevance for the pathogenesis of inflammation. Nitrix Oxide 2006;14:169-79.
153. Shacter E, Beecham EJJ, X Covey JM, Kohn KW, Potter M. Activated neutrophils induce prolonged DNA damage in neighboring cells. Carcinogenesis 1988; 9: 2297-304.
154. Levy JH. The human inflammatory response. J Cardiovasc Pharmacol 1996; 27: S31-7.
155. Simon SI, Goldsmith HL. Leukocyte adhesion dynamics in shear flow. Ann Biomed Eng 2002; 30: 315-32.
156. Cronstein BN, Weissmann G. The adhesion molecules of inflammation. Arthritis Rheum 1993; 36: 147-57.
157. Panés J, Granger N. Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease. Gastroenterology 1998; 114: 1066-90.
158. Vietor I, Schwenger P, Li W, Schlessinger J, Vilcek J. Tumor necrosis factor-induced activation and increased tyrosine phosphorylation of mitogen-activated protein (MAP) kinase in human fibroblasts. J Biol Chem 1993; 268: 18994-9.
159. Wallace JL, Ma L. Inflammatory mediators in gastrointestinal defense and injury. Exp Biol Med 2001; 226: 1003-15.
160. Harlan JM. Neutrophil-mediated vascular injury. Acta Med Scand 1987; Suppl. 715: 123-9.
161. DiPietro L. Wound healing: the role of the macrophage and other immune cells. Shock 1995; 4: 233-40.
162. Fritsch C. Simon-Assmann P. Kedinger M. Evans GS. Cytokines modulate fibroblast phenotype and epithelialstroma interactions in rat intestine. Gastroenterology 1997; 112: 826-38.
163. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990; 87: 1620-24.
164. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996; 271: C1424-C1437.
165. Delaney CA, Tyrberg B, Bouwens L, Vaghef H, Hellman B, Eizirik DL. Sensitivity of human pancreatic islets to peroxynitrite-induced cell dysfunction and death. FEBS Lett 1996; 394: 300-6.
166. Szabó C, Zingarelli B, O'Connor M, Salzman AL. DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc Natl Acad Sci USA 1996; 93: 1753-8.
167. Zingarelli B, O'Connor M, Wong H, Salzman AL, Szabó C. Peroxynitrite-mediated DNA strand breakage activates polyadenosine diphosphate ribosyl synthetase and causes cellular energy depletion in macrophages stimulated with bacterial lipopolysaccharide. J Immunol 1996; 156: 350-8.
168. Szabó C, Virág L, Cuzzocrea S, Scott GS, Hake P, O'Connor MP, et al. Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly (ADP-ribose) synthetase. Proc Natl Acad Sci USA 1998; 95: 3867-72.
169. Zhang J, Dawson VL, Dawson TM, Snyder SH. Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. Science 1994; 263: 687-9.
170. Snyder SH. No NO prevents parkinsonism. Nat Med 1996; 2: 965-6.
171. Bai P, Bakondi E, Szabo E, Gergely P, Szabo C, Virág L. Partial
172. Bode AM, Dong Z. In: Bao Y, Fenwick R, Eds, Phytochemicals in Health and Disease. New York, Marcel Dekker 2004; 257-84.
173. Chun KS, Surh YJ. Signal transduction pathways regulating cyclooxygenase-2 expression: potencial molecular targets for chemoprevention. Biochem Pharmacol 2004; 68: 1089-100.
174. Dorai T, Aggarwal BB. Role of chemopreventive agents in cancer therapy (mini-review). Cancer Lett 2004; 215: 129-40.
175. Lee FS, Hagler J, Chen ZJ, Maniatis T. Activation of the IkB alpha kinase complex by MEKK1, a kinase of the JNK pathway. Cell 1997; 88: 213-22.
176. Schwenger P, Alpert D, Skolnik EY, Vilcek J. Activation of p38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IkBa phosphorylation and degradation. Mol Cell Biol 1998; 18: 78-84.
177. Karin M. The beginning of the end: IjB kinase (IKK) and NfjB activation. J Biol Chem 1999; 274: 27339-42.
178. Bode AM, Dong Z. Targeting signal transduction pathways by chemopreventive agents (review). Mutat Res 2004; 555: 33-51.
179. Zingarelli B, Salzman AL, Szabo C. Genetic disruption of poly (ADP-ribose) synthetase inhibits the expression of Pselectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury. Circ Res 1998; 83: 85-94.
180. Rapizzi E, Fossati S, Moroni F, Chiarugi A. Inhibition of poly(ADP-ribose) glycohydrolase by gallotannin selectively upregulates expression of proinflammatory genes. Mol Pharmacol 2004; 66: 890-8.
181. Hassa PO, Covic M, Hasan S, Imhof R, Hottiger MO. The enzymatic and DNA binding activity of PARP-1 are not required for NF-kB coactivator function. J Biol Chem 2001; 276: 45588-97.
182. Berger NA. Oxidant-induced cytotoxicity: a challenge for metabolic modulation. Am J Respir Cell Mol Biol 1991; 4: 1-3.
183. Cochrane CG. Cellular injury by oxidants. Am J Med 1991; 91: S23-S30.
184. Decker P, Muller S. Modulating poly (ADP-ribose) polymerase activity: Potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress. Curr Pharm Biotechnol 2002; 3: 275-83.
185. Szabó C, Lim LH, Cuzzocrea S, Getting SJ, Zingarelli B, Flower RJ, et al. Inhibition of poly (ADP-ribose) synthetase exerts anti-inflammatory effects and inhibits neutrophil recruitment. J Exp Med 1997; 186: 1041-9.
186. Cuzzocrea S, Zingarelli B, Gilad E, Hake P, Salzman AL, Szabó C. Protective effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthase in a carrageenan-induced model of local inflammation. Eur J Pharm 1998; 342: 67-76.
187. Zingarelli B, Szabo C, Salzman AL. Blockade of poly(ADP-ribose) synthetase inhibits neutrophil recruitment, oxidant generation, and mucosal injury in murine colitis. Gastroenterology 1999; 116: 335-45.
188. Szabó C, Dawson VL. Role of poly (ADP-ribose) synthetase activation in inflammation and reperfusion injury. Trends Pharmacol Sci 1998; 19: 287-98.
189. Cabeza J, Motilva V, Martín MJ, Alarcón de la Lastra C. Mechanisms involved in gastric protection of melatonin on ischemia-reperfusion-induced oxidative damage in rats. Life Sci 2001; 68: 1405-15.
190. Szabó C, Cuzzocrea S, Zingarelli B, O'Connor M, Salzman AL. Endothelial dysfunction in a rat model of endotoxic shock. Importance of the activation of poly (ADP-ribose) synthetase by peroxynitrite. J Clin Invest 1997; 100: 723-35.
191. Hiromatsu Y, Sato M, Tanaka K, Ishisaka N, Kamachi J, Nonaka K. Inhibitory effects of nicotinamide on intercellular adhesion molecule-1 expression on cultured human thyroid cells. Immunology 1993; 80:330-2.
192. Ha HC, Snyder SH. Poly(ADP-ribose) polymerase-1 in the nervous system. Neurobiol Dis 2000; 7: 225-39.
193. Cole K, Perez-Polo JR. Neuronal trauma model: in search of Thanatos. Int J Dev Neurosci 2004; 22: 485-96.
194. Strosznajder RP, Jesko H, Zambrzycka A. Poly(ADP-ribose) polymerase: the nuclear target in signal transduction and its role in brain ischemia-reperfusion injury. Mol Neurobiol 2005; 31: 149-67.
195. Ulrich O, Diestel A, Eyupoglu IY, Nitsch R. Regulation of microglial expression of integrins by poly(ADP-ribose) polymerase-1. Nat Cell Biol 2001; 3: 1035-42.
196. Satchell MA, Zhang X, Kochanek PM, Dixon CE, Jenkins LW, Melick J, et al. A dual role for poly-ADP-ribosylation in spatial memory acquisition after traumatic brain injury in mice involving NAD+ depletion and ribosylation of 14-3-3 gamma. J Neurochem 2003; 85: 697-708.
197. Cohen-Armon M, Visochek L, Katzoff A, Levitan D, Susswein AJ, Klein R, et al. Long-term memory requires polyADP-ribosylation. Science 2004; 304: 1820-2.
198. Gu Y, Sarnecki C, Aldape RA, Livingston DJ, and Su MS. Cleavage of poly(ADP-ribose) polymerase by interleukin-1 beta converting enzyme and its homologs TX and Nedd-2. J Biol Chem 1995; 270: 18715-8.
199. Radons J, Heller B, Burkle A, Hartmann B, Rodriguez ML, Kroncke KD, et al. Nitric oxide toxicity in islet cells involves poly(ADP-ribose) polymerase activation and concomitant NAD+ depletion. Biochem Biophys Res Commun 1994; 199: 1270-7.
200. Zhang J, Pieper A, Snyder SH. Poly(ADP-ribose) synthetase activation: an early indicator of neurotoxic DNA damage. J Neurochem 1995; 65: 1411-4.
201. Mandir AS, Poitras MF, Berliner AR, Herring WJ, Guastella DB, Feldman A, et al. NMDA but not non-NMDA excitotoxicity is mediated by poly(ADP-ribose) polymerase. J Neurosc 2000; 20: 8005-11.
202. Pieper AA, Blackshaw S, Clements EE, Brat DJ, Krug DK, White AJ, et al. Poly (ADP-ribosyl)ation basally activated by DNA strand breaks reflects glutamate-nitric oxide neurotransmission. Proc Natl Acad Sci USA 2000; 97: 1845-50.
203. Pieper AA, Verma A, Zhang J, Snyder SH. Poly(ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol Sci 1999; 20: 171-81.
204. Lo EH, Bosque-Hamilton P, Meng W. Inhibition of poly(ADPribose) polymerase: reduction of ischemic injury and attenuation of N-methyl-D-aspartate-induced neurotransmitter dysregulation. Stroke 1998; 29: 830-6.
205. Cosi C, Suzuki H, Milani D, Facci L, Menegazzi M, Vantini G, et al. Poly(ADP-ribose) polymerase: early involvement in glutamate-induced neurotoxicity in cultured cerebellar granule cells. J Neurosci Res 1994; 39: 38-46.
206. Choi DW. Glutamate receptors and the induction of excitotoxic neuronal death. Prog Brain Res 1994; 100: 47-51.
207. Hammer B, Parker WDJ, Bennett JPJ. NMDA receptors increase OH radicals in vivo by using nitric oxide synthase and protein kinase C. Neuroreport 1993; 5: 72-4.
208. Meldrum B, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 1990; 11: 379-87.
209. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994; 330: 613-22.
210. Eliasson MJ, Sampei K, Mandir AS, Hurn PD, Traystman RJ, Bao J, et al. Poly-(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat Med 1997; 3: 1089-95.
211. Meli E, Pangallo M, Baronti R, Chiarugi A, Cozzi A, Pellegrini-Giampietro DE, et al. Poly(ADP-ribose) polymerase as a key player in excitotoxicity and post-ischemic brain damage. Toxicol Lett 2003; 139: 153-62.
212. Endres M, Wang ZQ, Namura S, Waeber C, Moskowitz MA. Ischemic brain injury is mediated by the activation of poly(ADPribose) polymerase. J Cereb Blood Flow Metab 1997; 17: 1143-51.
213. Tokime T, Nozaki K, Sugino T, Kikuchi H, Hashimoto N, Ueda K. Enhanced poly(ADP-ribosyl)ation after focal ischemia in rat brain. J Cereb Blood Flow Metab 1998; 18: 991-7.
214. Takahashi K, Pieper AA, Croul SE, Zhang J, Snyder SH, Greenberg JH. Post-treatment with an inhibitor of poly(ADPribose) polymerase attenuates cerebral damage in focal ischemia. Brain Res 1999; 829: 46-54.
215. Takahashi K, Greenberg JH. The effect of reperfusion on neuroprotection using an inhibitor of poly(ADP-ribose) polymerase. Neuroreport 1999; 10: 2017-22.
216. Ding Y, Zhou Y, Lai Q, Li J, Gordon V, Diaz FG. Longterm neuroprotective effect of inhibiting poly(ADP-ribose) polymerase in rats with middle cerebral artery occlusion using a behavioral assessment. Brain Res 2001; 915: 210-7.
217. Chiarugi A, Moskowitz MA. Poly(ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders. J Neurochem 2003; 85: 306-17.
218. Ullrich O, Diestel A, Eyupoglu IY, Nitsch R. Regulation of microglial expression of integrins by poly(ADP-ribose) polymerase-1. Nat Cell Biol 2001; 3: 1035-42.
219. Yu SW, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, Poirier GG, et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 2002; 297: 259-63.
220. Yu SW, Wang H, Dawson TM, Dawson VL. Poly(ADP-ribose) polymerase-1 and apoptosis inducing factor in neurotoxicity. Neurobiol Dis 2003; 14: 303-17.
221. Komjati K, Mabley JG, Virág L, Southan GJ, Salzman AL, Szabo C. Poly(ADP-ribose) polymerase inhibition protect neurons and the white matter and regulates the translocation of apoptosis-inducing factor in stroke. Int J Mol Med 2004; 13: 373-82.
222. Cao G, Clark RS, Pei W, Yin W, Zhang F, Sun FY, et al. Translocation of apoptosis-inducing factor in vulnerable neurons after transient cerebral ischemia and in neuronal cultures after oxygen-glucose deprivation. J Cereb Blood Flow Metab 2003; 23: 1137-50.
223. Zhu C, Qiu L, Wang X, Hallin U, Cande C, Kroemer G, et al. Involvement of apoptosis-inducing factor in neuronal death after hypoxia-ischemia in the neonatal rat brain. J Neurochem 2003; 86: 306-17.
224. Plesnila N, Zhu C, Culmsee C, Groger M, Moskowitz MA, Blomgren K. Nuclear translocation of apoptosis-inducing factor after focal cerebral ischemia. J Cereb Blood Flow Metab 2004; 24: 458-66.
225. Lee CS, Schulzer M, Mak EK, Snow BJ, Tsui JK, Calne S, et al. Clinical observations on the rate of progression of idiopathic Parkinsonism. Brain 1994; 117: 501-7.
226. Schapira AH. Neurotoxicity and the mechanisms of cell death in Parkinson's disease. Adv Neurol 1996; 69: 161-5.
227. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003; 302: 819-22.
228. Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 1998; 339: 1044-53.
229. Lang AE, Lozano AM. Parkinson's disease. Second of two parts. N Engl J Med 1998; 339: 1130-43.
230. Dawson TM. New animal models for Parkinson's disease. Cell 2000; 101: 115-8.
231. Forno LS, DeLanney LE, Irwin I, Langston JW. Similarities and differences between MPTP-induced parkinsonism and Parkinson's disease. Neuropathologic considerations. Adv Neurol 1993; 60: 600-8.
232. Langston JW. The etiology of Parkinson's disease with emphasis on the MPTP story. Neurology 1996; 47: S153-60.
233. Mandir AS, Przedborski S, Jackson-Lewis V, Wang ZQ, Simbulan-Rosenthal CM, Smulson ME, et al. Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc Natl Acad Sci USA 1999; 96: 5774-9.
234. Turski L, Bressler K, Rettig KJ, Loschmann PA, Wachtel H. Protection of substantia nigra from MPP+ neurotoxicity by N-methyld-aspartate antagonists. Nature 1991; 349: 414-8.
235. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 1997; 69: 1196-203.
236. Wang H, Shimoji M, Yu SW, Dawson TM, Dawson VL. Apoptosis inducing factor and PARP-mediated injury in the MPTP mouse model of Parkinson's disease. Ann NY Acad Sci 2003; 991: 132-9.
237. Cosi C, Suzuki H, Skaper SD, Milani D, Facci L, Menegazzi M, et al. Poly(ADP-ribose) polymerase (PARP) revisited. A new role for an old enzyme: PARP involvement in neurodegeneration and PARP inhibitors as possible neuroprotective agents. Ann NY Acad Sci 1997; 825: 366-79.
238. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996; 19: 312-8.
239. Volicer M. Free radicals in the development of Alzheimer's disease. Nurobiol Aging 1990; 11: 567-71.
240. Benzi G, Moretti A. Are reactive oxygen species involved in Alzheimer's disease? Neurobiol Aging 1995; 16: 661-74.
241. Mattson MP, Guo Q, Furukawa K, Pedersen WA. Presenilins, the endoplasmic reticulum, and neuronal apoptosis in Alzheimer's disease. J Neurochem 1998; 70: 1-14.
242. Montine TJ, Markesbery WR, Zackert W, Sanchez SC, Roberts LJ III, Morrow JD. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients. Am J Pathol 1999; 155: 863-8.
243. Koppaka V, Axelsen PH. Accelerated accumulation of amyloid β-proteins on oxidatively damaged lipid membranes. Biochemistry 2000; 39: 10011-6.
244. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 1997; 68: 2092-7.
245. Yan SD, Chen X, Schmidt AM, Brett J, Godman G, Zou YS, et al. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 1994; 91: 7787-91.
246. Harris ME, Hensley K, Butterfield DA, Leedle RA, Carney JM. Direct evidence of oxidative injury produced by the Alzheimer's beta-amyloid peptide (1-40) in cultured hippocampal neurons. Exp Neurol 1995; 131: 193-202.
247. Harris ME, Carney JM, Cole PS, Hensley K, Howard BJ, Martin L, et al. Beta-Amyloid peptide-derived, oxygen-dependent free radicals inhibit glutamate uptake in cultured astrocytes: implications for Alzheimer's disease. Neuroreport 1995; 6: 1875-9.
248. Mark RJ, Blanc EM, Mattson MP. Amyloid beta-peptide and oxidative cellular injury in Alzheimer's disease. Mol Neurobiol 1996; 12: 211-24.
249. Keller JN, Pang Z, Geddes JW, Begley JG, Germeyer A, Waeg G, et al. Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: role of the lipid peroxidation product 4-hydroxynonenal. J Neurochem 1997; 69: 273-84.
250. Butterfield DA, Hensley K, Harris M, Mattson M, Carney J. Beta-amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence-specific fashion: implications for Alzheimer's disease. Biochem Biophys Res Commun 1994; 200: 710-15.
251. Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, et al. A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer's disease. Proc Natl Acad Sci USA 1994; 91: 3270-4.
252. Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000; 71: 621S-629S.
253. Yao ZX, Drieu K, Szweda LI. Papadopoulos, V. Free radicals and lipid peroxidation do not mediate β-amyloid-induced neuronal cell death. Brain Res 1999; 847: 203-10.
254. Kruman II, Culmsee C, Chan SL, Kruman Y, Guo Z, Penix L, Mattson SP. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000; 20: 6920-6.
255. Birkmayer JG. Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type. Ann Clin Lab Sci 1996; 26: 1-9.
256. Scott GS, Jakeman LB, Stokes BT, and Szabo C. Peroxynitrite production and activation of poly (adenosine diphosphate-ribose) synthetase in spinal cord injury. Ann Neurol 1999; 45: 120-4.
257. Genovese T, Mazzon E, Muia C, Patel NS, Threadgill MD, Bramanti P, et al. Inhibitors of poly(ADP-ribose) polymerase modulate signal transduction pathways and secondary damage in experimental spinal cord trauma. J Pharmacol Exp Ther. 2005; 312: 449-57.
258. Casey PJ, Black JH, Szabo C, Frosch M, Albadawi H, Chen M, et al. Poly(adenosine diphosphate ribose) polymerase inhibition modulates spinal cord dysfunction after thoracoabdominal aortic ischemia-reperfusion. J Vasc Surg 2005; 41: 99-107.
259. Weise J, Isenmann S, Bahr M. Increased expression and activation of poly(ADP-ribose) polymerase (PARP) contribute to retinal ganglion cell death following rat optic nerve transection. Cell Death Differ 2001; 8: 801-7.
260. Kauppinen TM, Suh SW, Genain CP, Swanson RA. Poly(ADP-ribose) polymerase-1 activation in a primate model of multiple sclerosis. J Neurosci Res 2005; 81:190-8.
261. Ruuls SR, Bauer J, Sontrop K, Huitinga I, t'Hart BA, Dijkstra CD. Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats. J Neuroimmunol 1995; 56: 207-17.
262. Malfroy B, Doctrow SR, Orr PL, Tocco G, Fedoseyeva EV, Benichou G. Prevention and suppression of autoimmune encephalomyelitis by EUK-8, a synthetic catalytic scavenger of oxygen-reactive metabolites. Cell Immunol 1997; 177: 62-8.
263. Scott GS, Hake P, Kean RB, Virág L, Szabo C, Hooper DC. Role of poly(ADP-ribose) synthetase activation in the development of experimental allergic encephalomyelitis. J Neuroimmunol 2001; 117: 78-86.
264. Scott GS, Kean RB, Mikheeva T, Fabis MJ, Mabley JG, Szabo C, et al. The therapeutic effects of PJ34 N-(6-oxo-5,6- dihydrophenanthridin-2-yl)-N,N-dimethylacetamide.HC1], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation. J Pharmacol Exp Ther 2004; 310(3): 1053-61
265. Chiarugi A. Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats, Br J Pharmacol 2002; 137: 761-70.
266. Wallstrom E, Diener P, Ljungdahl A, Khademi M, Nilsson CG, Olsson T. Memantine abrogates neurological deWcits, but not CNS in Xammation, in Lewis rat experimental autoimmune encephalomyelitis. J Neurol Sci 1996; 137: 89-96.
267. Bolton C, Paul C. MK-801 limits neurovascular dysfunction during experimental allergic encephalomyelitis. J Pharmacol Exp Ther 1997; 282: 397-402.
268. Kaplin AI, Deshpande DM, Scott E, Krishnan C, Carmen JS, Shats I, et al. IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J Clin Invest 2005;115: 2731-41.
269. Cuzzocrea S, McDonald MC, Mazzon E, Dugo L, Serraino I, Threadgill M, et al. Effects of 5-aminoisoquinolinone, a watersoluble, potent inhibitor of the activity of poly(ADP-ribose) polymerase, in a rodent model of lung injury. Biochem Pharmacol 2002; 63: 293-304.
270. Shimoda K, Murakami K, Enkhbaatar P, Traber LD, Cox RA, Hawkins HK, et al. Effect of poly(ADP-ribose) synthetase inhibition on burn and smoke inhalation injury in sheep. Am J Physiol Lung Cell Mol Physiol 2003; 285: L240-9.
271. Murakami K, Enkhbaatar P, Shimoda K, Cox RA, Burke AS, Hawkins HK, et al. Inhibition of poly(ADP-ribose) polymerase attenuates acute lung injury in an ovine model of sepsis. Shock 2004; 21:126-33.
272. Genovese T, Mazzon E, Di Paola R, Muia C, Threadgill MD, Caputi AP, et al. Inhibitors of poly(ADP-ribose) polymerase modulate signal transduction pathways and the development of bleomycin-induced lung injury. J Pharmacol Exp Ther 2005; 313: 529-38.
273. Holgate ST. Airway inflammation and remodeling in asthma: current concepts. Mol Biotechnol 2002; 22:179-89.
274. Cohn L, Elias JA, Chupp GL. Asthma: mechanisms of disease persistence and progression. Annu Rev Immunol 2004; 22:789-815.
275. Lemanske Jr RF. Origins and treatment of airway inflammation in childhood asthma. Pediatr Pulmonol Suppl 2001; 21: 17-25.
276. Magnan A, Boniface S, Mely L, Romanet S, Mamessier E, Vervloet D. Cytokines, from atopy to asthma: the Th2 dogma revisited. Cell Mol Biol (Noisy-le-grand) 2001; 47: 679-87.
277. Renauld JC. New insights into the role of cytokines in asthma. J Clin Pathol 2001; 54: 577-89.
278. Barnes PJ, Chung KF, Page CP. Inflammatory mediators of asthma: an update. Pharmacol Rev 1998; 50: 515-96.
279. Boulares AH, Zoltoski AJ, Sherif ZA, Jolly P, Massaro D, Smulson ME. Gene knockout or pharmacological inhibition of poly(ADPribose) polymerase-1 prevents lung inflammation in a murine model of asthma. Am J Respir Cell Mol Biol 2003; 28: 322-9.
280. Virág L, Bai P, Bak I, Pacher P, Mabley JG, Liaudet L, et al. Effects of poly(ADP-ribose) polymerase inhibition on inflammatory cell migration in a murine model of asthma. Med Sci Monit 2004; 10: BR77-83.
281. Suzuki Y, Masini E, Mazzocca C, Cuzzocrea S, Ciampa A, Suzuki H, et al. Inhibition of poly(ADP-ribose) polymerase prevents allergen-induced asthma-like reaction in sensitized Guinea pigs. J Pharmacol Exp Ther 2004; 311: 1241-8.
282. Farivar AS, Woolley SM, Fraga CH, Thomas R, Salzman AL, Szabo C, et al. Intratracheal poly (ADP) ribose synthetase inhibition ameliorates lung ischemia reperfusion injury. Ann Thorac Surg 2004; 77: 1938-43.
283. Woolley SM, Farivar AS, Naidu BV, Salzman A, Szabo C, Thomas R, et al. Role of poly (ADP) ribose synthetase in lung ischemia-reperfusion injury. J Heart Lung Transplant 2004; 23: 1290-6.
284. Szabó G, Soos P, Mandera S, Heger U, Flechtenmacher C, Bahrle S, et al. INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation. Shock 2004; 21: 426-32.
285. Farivar AS, Woolley SM, Naidu BV, Fraga CH, Byrne K, Thomas R, et al. Poly (ADP) ribose synthetase inhibition reduces obliterative airway disease in rat tracheal allografts. J Heart Lung Transplant 2004; 23: 993-1002.
286. Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med 1998; 157: 1666-80.
287. Bellingan GJ. The pulmonary physician in critical care* 6: the pathogenesis of ALI/ARDS. Thorax 2002; 57: 540-6.
288. Veres B, Radnai B, Gallyas Jr F, Varbiro G, Berente Z, Osz E, et al. Regulation of kinase cascades and transcription factors by a poly(ADP-ribose) polymerase-1 inhibitor, 4-hydroxyquinazoline, in lipopolysaccharide-induced inflammation in mice. J Pharmacol Exp Ther 2004; 310: 247-55.
289. Kiefmann R, Heckel K, Doerger M, Schenkat S, Kupatt C, Stoeckelhuber M, et al. Role of PARP on iNOS pathway during endotoxin-induced acute lung injury. Intensive Care Med 2004; 30: 1421-31.
290. Szabó C, Saunders C, O'Connor M, Salzman AL. Peroxynitrite causes energy depletion and increases permeability via activation of poly (ADP-ribose) synthetase in pulmonary epithelial cells. Am J Respir Cell Mol Biol 1997; 16: 105-9.
291. Huang H, McIntosh JL, Fang L, Szabo C, Hoyt DG. Integrinmediated suppression of endotoxin-induced DNA damage in lung endothelial cells is sensitive to poly(ADP-ribose) polymerase-1 gene deletion. Int J Mol Med 2003; 12: 533-40.
292. Szabó A, Salzman AL, Szabó C. Poly (ADP-ribose) synthetase activation mediates pulmonary microvascular and intestinal mucosal dysfunction in endotoxin shock. Life Sci 1998; 63: 2133-9.
293. Heckel K, Kiefmann R, Dorger M, Stoeckelhuber M, Goetz AE. Colloidal gold particles as a new in vivo marker of early acute lung injury. Am J Physiol Lung Cell Mol Physiol 2004; 287: L867-78.
294. Pieper AA, Walles T, Wei G, Clements EE, Verma A, Snyder SH, and Zweier JL Myocardial postischemic injury is reduced by poly-ADPripose polymerase-1 gene disruption. Mol Med 2000; 6: 271-282.
295. Liaudet L, Szabo E, Timashpolsky L, Virág L, Cziraki A, Szabo C. Suppression of poly (ADP-ribose) polymerase activation by 3-aminobenzamide in a rat model of myocardial infarction: long-term morphological and functional consequences. Br J Pharmacol 2001; 133: 1424-30.
296. Gilad E, Zingarelli B, Salzman AL, and Szabo C Protection by inhibition of poly (ADP-ribose) synthetase against oxidant injury in cardiac myoblasts in vitro. J Mol Cell Cardiol 1997; 29: 2585-97.
297. Bowes J, McDonald MC, Piper J, Thiemermann C. Inhibitors of poly (ADP-ribose) synthetase protect rat cardiomyocytes against oxidant stress. Cardiovasc Res 1999; 41:126-134.
298. Halmosi R, Berente Z, Osz E, Toth K, Literati-Nagy P, Sumegi B. Effect of poly(ADP-ribose) polymerase inhibitors on the ischemia-reperfusion-induced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system. Mol Pharmacol 2001; 59: 1497-505.
299. Szabó G, Bahrle S, Stumpf N, Sonnenberg K, Szabo EE, Pacher P, et al. Poly(ADP-Ribose) polymerase inhibition reduces reperfusion injury after heart transplantation. Circ Res 2002; 90:100-6.
300. Yang Z, Zingarelli B, Szabó C. Effect of genetic disruption of poly (ADP-ribose) synthetase on delayed production of inflammatory mediators and delayed necrosis during myocardial ischemia-reperfusion of injury. Shock 2000; 13: 60-6.
301. Liaudet L, Yang Z, Affar B, Szabó C. Myocardial ischemic preconditioning in rodents is dependent on poly(ADP-ribose) synthetase. Mol Med 2001; 7: 406-17.
302. Fiorillo C, Pace S, Ponziani V, Nediani C, Perna AM, Liguori P, et al. Poly(ADP-ribose) polymerase activation and cell injury in the course of rat heart heterotopic transplantation. Free Radic Res 2002; 36: 79-87.
303. Fiorillo C, Ponziani V, Giannini L, Cecchi C, Celli A, Nediani C, et al. Beneficial effects of poly(ADP-ribose) polymerase inhibition against the reperfusion injury in heart transplantation. Free Radic Res 2003; 37: 331-9.
304. Farivar AS, McCourtie AS, MacKinnon-Patterson BC, Woolley SM, Barnes AD, Chen M, et al. Poly (ADP) ribose polymerase inhibition improves rat cardiac allograft survival. Ann Thorac Surg 2005; 80: 950-6.
305. Pacher P, Liaudet L, Soriano FG, Mabley J, Szabo E, Szabo C. The Role of poly(ADP-ribose) polymerase in the development of myocardial and endothelial dysfunction in diabetes mellitus. Diabetes 2002; 51: 514-521.
306. Skuta G, Fischer GM, Janaky T, Kele Z, Szabo P, Tozser J, et al. Molecular mechanism of the short-term cardiotoxicity caused by 2′, 3′-dideoxycytidine (DdC): modulation of reactive oxygen species levels and ADPribosylation reactions. Biochem Pharmacol 1999; 58: 1915-25.
307. Szabados E, Fischer GM, Toth K, Csete B, Nemeti B, Trombitas K, et al. Role of reactive oxygen species and poly-ADP-ribose polymerase in the development of AZT-induced cardiomyopathy in rat. Free RadicBiol Med 1999; 26: 309-17.
308. Pacher P, Liaudet L, Bai P, Virág L, Mabley J, Hasko G, et al. Activation of poly(ADP-ribose) polymerase contributes to the development of doxorubicin-induced heart failure. J Pharmacol Exp Ther 2002; 300: 862-7.
309. Fiocchi C. Inflammatory bowel disease. Current concepts of pathogenesis and implications for therapy. Minerva Gastroenterol Dietol 2002; 48: 215-26.
310. Guo X, Wang WP, Ko JK, Cho CH. Involvement of neutrophils and free radicals in the potentiating effects of passive cigarette smoking on inflammatory bowel disease in rats. Gastroenterology 1999; 117: 884-92.
311. Kruidenier, L, Verspaget HW. Oxidative stress as a pathogenic factor in inflammatory bowel disease - radicals or ridiculous? Aliment. Pharmacol Ther 2002; 16: 1997-2015.
312. Abreu MT. The pathogenesis of inflammatory bowel disease: translational implications for clinicians. Curr Gastroenterol Rep 2002; 4: 481-9.
313. Shiratora Y, Acki S, Takada H, Kiriyarna H, Ohto K, Hai K, et al. Oxygen-derived free radical generating capacity of polymorphonuclear cells in patients with ulcerative colitis. Digestión 1989; 44:163-71.
314. Kitahora T, Suzuki Ir, Asakura H, Yoshida T, Suematsu M, Watanabe M, et al. Active oxygen species generated by monocytes and polymorphonuclear cells in patients in Crohn's disease. Dig Dis Sci 1998; 33: 951-5.
315. Siegmund B. Interleukin-1beta converting enzyme (caspase-1) in intestinal inflammation. Biochem Pharmacol 2002; 64: 1-8.
316. Sartor RB. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology 1994; 106: 533-9.
317. Simmonds NJ, Rampton DS. Inflammatory bowel disease: a radical view. Gut 1994; 34: 861-5.
318. Rogler G, Andus T. Cytokines in inflammatory bowel disease. World J Surg 1998; 22: 382-9.
319. Kankuri E, Vaali K, Knowles R, Lahde M, Korpela R, Vapaatalo H, et al. Suppression of acute experimental colitis by a highly selective inducible nitric-oxide synthase inhibitor. N-3-(aminomethyl)benzyl]acetamidine. J Pharmacol Exp Ther 2001; 298: 1128-32.
320. Menchen LA, Colon AL, Moro MA, Leza JC, Lizasoain I, Menchen P, et al. N-(3-(aminomethyl) benzyl)acetamidine, an inducible nitric oxide synthase inhibitor, decreases colonic inflammation induced by trinitrobenzene sulphonic acid in rats. Life Sci 2001; 69: 479-491.
321. Ardite E, Panes J, Miranda M, Salas A, Elizalde JI, Sans M, et al. Effects of steroid treatment on activation of nuclear factor-nB in patients with inflammatory bowel disease. Br J Pharmacol 1998; 124: 431-33.
322. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factorkB inflammatory bowel disease. Gut 1998; 42: 477-84.
323. Gonsky R, Deem RL, Hughes CC, Targan SR. Activation of the CD2 pathway in lamina propia T cells up-regulates functionally active AP-1 binding to the IL-2 promoter, resulting in messenger RNA transcription and IL-2 secretion. J Immunol 1998; 160: 4914-22.
324. Abreu-Martin MT, Palladino AA, Faris M, Carramanzana NM, Nel AE, Targan SR. Fas activates the JNK pathway in human colonic epithelial cells: lack of a direct role in apoptosis. Am J Physiol 1999; 276: G599-605.
325. Zingarelli B, Yang Z, Hake PW, Denenberg A, Wong HR. Absence of endogenous interleukin-10 enhances early stress response during postischemic injury in mice intestine. Gut 2001; 5:610-22.
326. Zingarelli B, O'Connor M, Hake PW. Inhibitors of poly(ADPribose) polymerase modulate signal transduction pathways in colitis. Eur J Pharmacol 2003; 469:183-94.
327. Jijon HB, Churchill T, Malfair D, Wessler A, Jewell LD, Parsons HG, et al. Inhibition of poly(ADP-ribose) polymerase attenuates inflammation in a model of chronic colitis. Am J Physiol Gastrointest Liver Physiol 2000; 279: G641-51.
328. Mazzon E, Dugo L, Li JH, Di Paola R, Genovese T, Caputi AP, et al. GPI 6150 a PARP inhibitor, reduces the colon injury caused by dinitrobenzene sulfonic acid in the rat. Biochem Pharmacol 2002; 64: 327-37.
329. Haskó G, Mabley JG, Németh ZH, Pacher P, Deitch EA, Szabó C. Poly(ADP-ribose) polymerase is a regulator of chemokine production: relevance for the pathogenesis of shock and inflammation. Mol Med 2002; 8: 283-9.
330. Watson AJ, JN Askew, RS Benson. Poly(adenosine diphosphate ribose) polymerase inhibition prevents necrosis induced by H2O2 but not apoptosis, Gastroenterology 1995; 109: 472-482.
331. Kennedy MS, Denenberg AG, Szabo C, Salzman AL. Poly (ADP-ribose) synthetase (PARS) mediates increased permeability induced by peroxynitrite in Caco-2BBe cells, Gastroenterology 1998; 114: 510-18.
332. Di Paola R, Mazzon E, Xu W, Genovese T, Ferrraris D, Muia C, et al. Treatment with PARP-1 inhibitors, GPI 15427 or GPI 16539, ameliorates intestinal damage in rat models of colitis and shock. Eur J Pharmacol 2005; 527: 163-71.
333. Zingarelli B, Hake PW, Burroughs TJ, Piraino G, O'connor M, Denenberg A. Activator protein-1 signalling pathway and apoptosis are modulated by poly(ADP-ribose) polymerase-1 in experimental colitis. Immunology 2004; 113: 509-17.
334. Popoff IH, Jijon B, Monia H, Tavernini M, Ma R, McKay K, et al. Antisense oligonucleotides to poly(ADP-ribose) polymerase-2 ameliorate colitis in interleukin-10-deWcient micem. J Pharmacol Exp Ther 2002; 303: 1145-54.
335. Harris Jr ED. Rheumatoid arthritis: pathophysiology and implication for therapy. N Engl J Med 1990; 323:996.
336. Arend WP, Dayer JM. Inhibition of the production and effect of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Athritis Rheum 1995; 38: 151-60.
337. Chen E, Keystone EC, Fish EN. Restricted cytokine expression in rheumatoid arthritis. Arthritis Rheum 1993; 36: 901-10.
338. Muller-Ladner U. Molecular and cellular interactions in rheumatoid synovium [review]. Curr Opin Rheumatol 1996; 8: 210-20.
339. Santos L, Tipping PG. Attenuation of adjuvant arthritis in rats by treatment with oxygen radical scavengers. Immunol Cell Biol 1994; 72: 406-14.
340. Kaur H, Edmonds SE, Blake DR, Halliwell B. Hydroxyl radical generation by rheumatoid blood and knee joint synovial fluid. Ann Rheum Dis 1996; 55: 915-20.
341. Grabowski PS, Macpherson H, Ralston SH. nitric oxide production in cells derived from the human joint. Br J Rheumatol 1996; 35: 207-12.
342. Hayashi T, Abe E, Yamate T, Taguchi Y, Jasin HE. Nitric oxide production by superficial and deep articular chondrocytes. Arthritis Rheum 1997; 40: 261-69.
343. Tomita T, Takeuchi E, Tomita N, Morishita R, Kaneko M, Yamamoto K, et al. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kB decoy oligodeoxynucleotides as a gene therapy. Arthritis Rheum 1999; 42: 2532-42.
344. Miesel R, Kurpisz M, Kroger H. Modulation of inflammatory arthritis by inhibition of poly(ADP ribose) polymerase. Inflammation 1995; 19: 379-87.
345. Kroger H, Miesel R, Dietrich A, Ohde M, Rajnavolgyi E, Ockenfels H. Synergistic effects of thalidomide and poly (ADPribose) polymerase inhibition on type II collagen-induced arthritis in mice. Inflammation 1996; 20: 203-15.
346. Salvemini D, Mazzon E, Dugo L, Serraino I, De Sarro A, Caputi AP, et al. Amelioration of joint disease in a rat model of collagen-induced arthritis by M40403, a superoxide dismutase mimetic. Arthritis Rheum 2001; 44: 2909-21.
347. Cuzzocrea S, Mazzon E, Paola RD, Genovese T, Muia C, Caputi AP, et al. Effects of combination M40403 and dexamethasone therapy on joint disease in a rat model of collagen-induced arthritis. Arthritis Rheum 2005; 52: 1929-40.
348. Garcia S, Bodano A, Gonzalez A, Forteza J, Gomez-Reino JJ, Conde C. Partial protection against collagen antibody-induced arthritis in PARP-1 deficient mice. Arthritis Res Ther 2005; 8: R14
349. Gay S, Gay RE, Koopman WJ. Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction? Ann Rheum Dis 1993; 52: S3S47.
350. Satoh K, Kikuchi S, Sekimata M, Kabuyama Y, Homma MK, Homma Y. Involvement of ErbB-2 in rheumatoid synovial cell growth. Arthritis Rheum 2001; 44: 260-265.
351. Kameoka M, Ota K, Tetsuka T, Tanaka Y, Itaya A, Okamoto T, et al. Evidence for regulation of NF-kappaB by poly(ADP-ribose) polymerase. Biochem J 2000; 346: 641-49.
352. Nirodi C, NagDas S, Gygi SP, Olson G, Aebersold R, Richmond A. A role for poly(ADP-ribose) polymerase in the transcriptional regulation of the melanoma growth stimulatory activity (CXCL1) gene expression. J Biol Chem 2001; 276: 9366-74.
353. Szabó C. Roles of poly(ADP-ribose)polymerase activation in the pathogenesis of diabetes mellitus and its complications. Pharmacol Res 2005; 52: 60-71.
354. Kleemann R, Rothe H, Kolb-Bachofen V, Xie QW, Nathan C, Martin S, et al. Transcription and translation of inducible nitric oxide synthase in the pancreas of prediabetic BB rats. FEBS Lett 1993; 328: 9-12.
355. Corbett JA, Wang JL, Sweetland MA, Lancaster Jr JR, McDaniel ML. Interleukin 1 beta induces the formation of nitric oxide by beta-cells purified from rodent islets of Langerhans. Evidence for the beta-cell as a source and site of action of nitric oxide. J Clin Invest 1992; 90: 2384-91.
356. Suschek C, Fehsel K, Kroncke KD, Sommer A, Kolb-Bachofen V. Primary cultures of rat islet capillary endothelial cells. Constitutive and cytokine-inducible macrophagelike nitric oxide synthases are expressed and activities regulated by glucose concentration. Am J Pathol 1994;145: 685-95.
357. Soriano FG, Virág L, Szabo C. Diabetic endothelial dysfunction: role of reactive oxygen and nitrogen species production and poly(ADP-ribose) polymerase activation. J Mol Med 2001; 79: 437-48.
358. Garcia Soriano F, Virág L, Jagtap P, Szabo E, Mabley JG, Liaudet L, et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 2001; 7: 108-13.
359. Szabó C, Zanchi A, Komjati K, Pacher P, Krolewski AS, Quist WC, et al. Poly(ADP-Ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. Circulation 2002; 106: 2680-86.
360. Minchenko AG, Stevens MJ, White L, Abatan OI, Komjati K, Pacher P, et al. Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J 2003; 17: 1514-16.
361. Li F, Szabo C, Pacher P, Southan GJ, Abatan OI, Charniauskaya T, et al. Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy. Diabetologia 2004; 47: 710-7.
362. Zheng L, Szabo C, Kern TS. Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes 2004; 53: 2960-7.
363. Obrosova IG, Julius UA. Role for poly(ADP-ribose) polymerase activation in diabetic nephropathy, neuropathy and retinopathy. Curr Vasc Pharmacol 2005; 3: 267-83.
364. Ceriello A. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia 2003; 46: M9-16.
365. Obrosova IG, Drel VR, Pacher P, Ilnytska O, Wang ZQ, Stevens MJ, et al. Oxidative-Nitrosative Stress and Poly(ADP-Ribose) Polymerase (PARP) Activation in Experimental Diabetic Neuropathy: The Relation Is Revisited. Diabetes 2005; 54: 3435-41.
366. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-20.
367. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C, et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 2003; 112: 1049-57.
368. Piconi L, Quagliaro L, Da Ros R, Assaloni R, Giugliano D, Esposito K, et al. Intermittent high glucose enhances ICAM-1, VCAM-1, E-selectin and interleukin-6 expression in human umbilical endothelial cells in culture: the role of poly(ADP-ribose) polymerase. J Thromb Haemost 2004; 2: 1453-9.
369. Tempera I, Cipriani R, Campagna G, Mancini P, Gatti A, Guidobaldi L, et al. Poly(ADP-ribose)polymerase activity is reduced in circulating mononuclear cells from type 2 diabetic patients. J Cell Physiol 2005; 205: 387-92.
370. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation.Diabetes 2003; 52: 2795-804.
371. Masutani M, Nozaki T, Nishiyama E, Shimokawa T, Tachi Y, Suzuki H, et al. Function of poly(ADP-ribose) polymerase in response to DNA damage: gene-disruption study in mice. Mol Cell Biochem 1999; 193: 149-52.
372. Mabley JG, Suarez-Pinzon WL, Hasko G, Salzman AL, Rabinovitch A, Kun E, et al. Inhibition of poly (ADP-ribose) synthetase by gene disruption or inhibition with 5-iodo-6-amino-1,2-benzopyrone protects mice from multiple-low-dose-streptozotocin-induced diabetes. Br J Pharmacol 2001; 133: 909-19.
373. Shima K, Hirota M, Sato M, Numoto S, Oshima I. Effect of poly(ADP-ribose) synthetase inhibitor administration to streptozotocin-induced diabetic rats on insulin and glucagon contents in their pancreas.Diabetes Res Clin Pract 1987; 3: 135-42.
374. Masiello P, Novelli M, Fierabracci V, Bergamini E. Protection by 3-aminobenzamide and nicotinamide against streptozotocin-induced beta-cell toxicity in vivo and in vitro. Res Commun Chem Pathol Pharmacol 1990; 69: 17-32.
375. Bouix O, Reynier M, Guintrand-Hugret R, Orsetti A. Protective effect of gamma-hydroxybutyrate and nicotinamide on low-dose streptozotocin-induced diabetes in mice. Horm Metab Res 1995; 27: 216-20.
376. O'Brien BA, Harmon BV, Cameron DP, Allan DJ. Nicotinamide prevents the development of diabetes in the cyclophosphamide-induced NOD mouse model by reducing beta-cell apoptosis. J Pathol 2000; 191: 86-92.
377. Akabane A, Kato I, Takasawa S, Unno M, Yonekura H, Yoshimoto T, et al. Nicotinamide inhibits IRF-1 mRNA induction and prevents IL-1 beta-induced nitric oxide synthase expression in pancreatic beta cells. Biochem Biophys Res Commun 1995; 215: 524-30.
378. Hoorens A, Pipeleers D. Nicotinamide protects human beta cells against chemically-induced necrosis, but not against cytokine-induced apoptosis. Diabetologia 1999; 42: 55-9.
379. Soriano FG, Pacher P, Mabley J, Liaudet L, Szabo C. Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. Circ Res 2001; 89: 684-91.
380. Suarez-Pinzon WL, Mabley JG, Power R, Szabo C, Rabinovitch A. Poly (ADP-ribose) polymerase inhibition prevents spontaneous and recurrent autoimmune diabetes in NOD mice by inducing apoptosis of islet-infiltrating leukocytes. Diabetes 2003; 52:1683-8.
381. Burkart V, Wang ZQ, Radons J, Heller B, Herceg Z, Stingl L, et al. Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin. Nat Med 1999; 5: 314-9.
382. Masutani M, Suzuki H, Kamada N, Watanabe M, Ueda O, Nozaki T, et al. Poly(ADP-ribose) polymerase gene disruption conferred mice resistant to streptozotocin-induced diabetes. Proc Natl Acad Sci USA 1999; 96: 2301-4.
383. Pieper AA, Brat DJ, Krug DK, Watkins CC, Gupta A, Blackshaw S, Verma A, Wang ZQ, Snyder SH. Poly(ADP-ribose) polymerasedeficient mice are protected from streptozotocin-induced diabetes. Proc Natl Acad Sci USA 1999; 96: 3059-64.
384. Gonzalez C, Menissier de Murcia J, Janiak P, Bidouard JP, Beauvais C, Karray S, et al. Unexpected sensitivity of nonobese diabetic mice with a disrupted poly (ADP-ribose) polymerase-1 gene to streptozotocin-induced and spontaneous diabetes. Diabetes 2002; 51:1470-6.
385. Abiyama T, Takasawa S, Nata K, Kobayashi S, Abe M, Sherwani NJ, et al. Activation of Reg gene, a gene for insulin-producing beta-cell regneration: poly(ADP-ribose) polymerase binds Reg promoter and regulates the transcription by autopoly(ADP-ribosyl)ation. Proc Natl Acad Sci USA 2001; 98: 48-53.